Scholar Rock Holding Corp (SRRK): Cash & Equivalents
$323.53M
As of 2025-12-31
$437.09M
As of 2026-06-30
+46.3%
3-year compound annual growth
+15.1%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $323.53M | +81.9% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $177.88M | +74.6% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $101.86M | -1.4% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $103.28M | -51.5% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $212.84M | +32.7% | 2023-03-07, Balance as of period end |
| 2020-12-31 | $160.36M | +341.7% | 2022-03-07, Balance as of period end |
| 2019-12-31 | $36.31M | -68.4% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $115.07M | +103.8% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $56.46M | n/a | 2019-03-19, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $323.53M | +81.9% |
| Amgen Inc (AMGN) | 2025-12-31 | $9.13B | -23.8% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Vericel Corp (VCEL) | 2025-12-31 | $100.09M | +34.3% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $713.00M | +206.0% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
Compare SRRK, AMGN, RGEN, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗